Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

2022164 citationsJournal Articlebronze Open Access

Authors

Zhijie Wang · Chinese Academy of Medical Sciences & Peking Union Medical College

Lin Wu · Central South University

Baolan Li · Capital Medical University

Ying Cheng · Jilin Province Tumor Hospital

Xiaoling Li · First Affiliated Hospital of Zhengzhou University

Xicheng Wang · Guangdong Pharmaceutical University

Liang Han

Abstract

Toripalimab plus chemotherapy significantly improves PFS and OS in patients with treatment-naive advanced NSCLC while having a manageable safety profile. Subgroup analysis showed the OS benefit was mainly driven by the nonsquamous subpopulation.

Topics & Keywords

Lung Cancer Treatments and Mutations Cancer Immunotherapy and Biomarkers Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 41, Issue 3, pp. 651-663

DOI: 10.1200/jco.22.00727

Field-Weighted Citation Impact: 23.71